.Nature Medicine, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a typical consequence of 11 months, clients with metastatic gastrointestinal cysts who obtained biomarker-matched treatments based upon distributing lump DNA profiling showed a better professional advantage than those receiving unequaled treatment.